AstraZeneca’s COVID-19 vaccine still has market potential despite an expected global oversupply of shots and delays in the vaccine’s approval in the United States, the company’s chief executive Pascal Soriot said on April 29.
GSK’s strong Q1 driven by COVID-19, returning demand for shingles vaccineAntibodies, Business, Business Intelligence, Consumer Health Care, Consumer Healthcare, Coronavirus Disease 2019 (COVID-19), Earnings per share (EPS), Financials, GlaxoSmithKline, Guidance, Leadership, Operations, Presentations, Quarterly results, Sales, Sales, Sales & Marketing, Sales Guidance, Shingles, Strikes, Therapeutics, Vaccines
GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Moderna to file for EUA of COVID-19 shot for very young kids by April endClinical Trials, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19), Coronavirus Vaccines, COVID-19 shots, COVID-19 Vaccine Guidance, COVID-19 Vaccines, Emergency Use Authorization (EUA), FDA, Kids, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&D, Therapeutics
Moderna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of the company’s COVID-19 vaccine among kids between the ages of six months to five years by the end of the month, a company spokesperson said.
Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
U.S. FDA aims to decide on strain selection for COVID boosters by JuneBNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccine Guidance, COVID-19 Vaccines, Guidance, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemics, Therapeutics, Vaccines
Top U.S. Food and Drug Administration officials on April 6 said the agency is aiming to decide by June whether to change the design of COVID-19 vaccines in order to combat future variants, even if it does not have all the necessary information to measure their effectiveness.
The American Medical Association (AMA) on January 5 criticized the government’s guidelines on quarantine and isolation in the United States, saying the guidance was “confusing” and risked further spread of COVID-19.
The U.S. Centers for Disease Control and Prevention (CDC) on January 4 backed the agency’s week-old guidance for people seeking to end their COVID-19 isolation at five days, adding they could take a rapid antigen test if they want to and can access one, but is not requiring that.
The World Health Organization updated its guidelines for COVID-19 treatments against the use of convalescent plasma for all cases of infection.
Participants in Novavax Inc.’s late-stage Covid-19 vaccine trial can be considered fully vaccinated two weeks after completing their two-dose vaccine regimen, the U.S. Centers for Disease Control and Prevention said on Aug. 30.
The U.S. Centers for Disease Control and Prevention on July 9 updated its guidance to help reopen schools in the fall, including recommending masking indoors for everyone who is not fully vaccinated and three feet of distance within classrooms.